Soros Fund Management LLC Decreased Valeant Pharmaceuticals Intl (Put) (VRX) Stake by $13.20 Million as Shares Declined

April 14, 2018 - By Darrin Badillo

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Corporate LogoDuring 2017 Q4 the big money sentiment decreased to 0.97. That’s change of 0.02, from 2017Q3’s 0.99. 51 investors sold all, 74 reduced holdings as VRX ratio fall. 67 grew positions while 54 funds took positions. Funds hold 169.66 million shares thus 0.12% less from 2017Q3’s 169.87 million shares. Highlander Mngmt Limited Liability Company reported 0.19% stake. Sg Americas Limited Liability Corp holds 0.28% of its capital in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 1.44M shs. State Street holds 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) or 153,117 shs. Earnest Prns Limited Com has 0% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 49 shs. Nexus Investment reported 37,055 shs stake. 1.89 million are held by Barclays Public Limited Liability Company. Td Asset Mngmt Inc holds 0.03% of its capital in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 1.13M shs. Valueact Limited Partnership reported 18.01M shs. San Francisco Sentry Inv Grp (Ca) reported 0.04% stake. Acadian Asset Mgmt Llc holds 368,617 shs. First Republic Invest Mngmt has invested 0.06% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Captrust Finance Advsr holds 0% or 2,300 shs in its capital. Academy Tx reported 622,146 shs or 3.57% of all its holdings. Deutsche Retail Bank Ag reported 0.04% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Toth Financial Advisory Corp has 0% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 1,000 shs.

VRX registered $876,370 net activity with 3 insider buys and 0 insider sales since March 8, 2018. Shares for $241,470 were bought by Herendeen Paul on Tuesday, March 13. 30,000 shs were bought by PAPA JOSEPH C, worth $481,500 on Tuesday, March 13.

In 2017Q4 SEC filling is reported George Soros’s stake in Valeant Pharmaceuticals Intl (Put) (VRX) which was decreased by 30.56%. 660,000 shares were sold by Soros Fund Management Llc as the company’s stock declined 28.77% with the market. The hedge fund run by George Soros is holding 1.50 million shares, compared to the 2.16 million from the previous quarter. And the announced value of the health care company is $31.17 million for the 2017Q4. $5.98B is Valeant Pharmaceuticals Intl (Put)’s MC. VRX reached $17.15 on during the last trading session after $0.52 change.Valeant Pharmaceuticals International, Inc. has volume of 10.80 million shares. Since April 14, 2017 VRX has risen 42.00% and is uptrending. VRX outperformed the S&P500 by 30.45%.

About $4.37B US Long portfolio the Soros Fund Management Llc manages. Its stake in Liberty Interactive Corp was rose by 152,000 shares to 402,000 shares valued at $21.80 million in 2017Q4, according to the filing. Soros Fund Management Llc has risen its stake in Nxp Semiconductors N V (NASDAQ:NXPI) and also increased its holding in American Eagle Outfitters Ne (NYSE:AEO) by 1.26 million shares in the quarter, for a total of 1.28M shares.

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on May, 8. They expect $0.66 earnings per share, down 76.43 % or $2.14 from last year’s $2.8 per share. VRX’s profit will be $230.25 million for 6.50 P/E if the $0.66 EPS becomes a reality. After $0.98 actual earnings per share reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -32.65 % negative EPS growth.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

In total 15 analysts cover Valeant Pharma (NYSE:VRX). “Buy” rating has 3, “Sell” are 4, while 8 are “Hold”. 20% are bullish. With $25.0 highest and $7.0 lowest [Target] Valeant Pharma has $16.27 average [Target] or -5.13% below the current ($17.15) price. 30 are the (NYSE:VRX)’s analyst reports since October 16, 2017 according to StockzIntelligence Inc. On Tuesday, January 16 H.C. Wainwright maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) with “Hold” rating. On Monday, October 30 BMO Capital Markets maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) with “Hold” rating. The company rating was upgraded by Deutsche Bank on Monday, March 5. On Tuesday, November 7 the stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Buy” rating given by Cantor Fitzgerald. On Friday, December 15 Mizuho maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) with “Underperform” rating. The stock rating was maintained by Mizuho with “Sell” on Wednesday, November 1. On Friday, January 19 the stock has “Buy” rating by Cantor Fitzgerald. The company rating was maintained by H.C. Wainwright on Thursday, November 9. On Monday, December 4 the firm earned “Hold” rating by BTIG Research. On Thursday, March 15 the firm has “Hold” rating given by H.C. Wainwright.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.